Teva Pharmaceutical Industries Limited
TEVAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, Teva Pharmaceutical Industries Limited (TEVA) is listed under Drug Manufacturers - Specialty & Generic. At a $37.30B market cap, Teva Pharmaceutical Industries Limited ranks as a large-cap company within healthcare. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Market Cap
$37.30B
Beta
0.86
P/E (TTM)
23.90
P/E (Fwd)
10.40
EPS (TTM)
$1.34
EPS (Fwd)
$3.08
ROE
21.6%
ROA
6.4%
Cash
$3.74B
Total Debt
$16.92B
Free CF
$2.61B
52W Change
99.4%
Annual Financials
Cash vs Debt
The company holds $3.74B in cash, though total debt stands at $16.92B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $2.61B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 21.6%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $14.93B to $17.26B.
Investors considering Teva Pharmaceutical Industries Limited should weigh the typical risks associated with TEVA's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing TEVA.